Bristol-Myers Squibb
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. The company was formed in 1989, following the merger of its predecessors Bristol-Myers and the Squibb Corporation. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, New York.
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
Its key products are:
- Abilify (aripiprazole)
- Atripla (efavirenz/emtricitabine/tenofovir)
- Avalide (irbesartan-hydrochlorothiazide)
- Avapro (irbesartan)
- Baraclude (entecavir)
- Bydureon (exenatide)
- Byetta (exenatide)
- Coumadin (warfarin)
- Eliquis (apixaban)
- Erbitux (cetuximab)
- Farxiga (Dapagliflozin)
- Ixempra (ixabepilone)
- Mucomyst (Acetylcysteine)
- Nulojix (belatacept)
- Onglyza (saxagliptin)
- Orencia (abatacept)
- Plavix (clopidogrel)
- Reyataz (atazanavir)
- Sprycel (dasatinib)
- Sustiva (efavirenz)
- Taxol (paclitaxel)
- Yervoy (ipilimumab)
Immuno-oncology drugs elotuzumab and nivolumab are currently in Phase III trials in Bristol-Myers Squibb's pipeline.
Latest Bristol-Myers Squibb News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze